Eton Pharmaceuticals (ETON) Cash from Operations Growth (3y) (2021 - 2025)
Eton Pharmaceuticals (ETON) Cash from Operations Growth (3y) (2021 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 8.25% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 52.97% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 5.90% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 43.42% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -10.08% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | -8.76% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 65.60% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Eton Pharmaceuticals | 1.76 Bn | 1.73 Bn | 25.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -82.39% |
| Sep 30, 2025 | 108.48% |
| Jun 30, 2025 | 47.88% |
| Mar 31, 2025 | 19.56% |
| Dec 31, 2024 | 46.93% |
| Sep 30, 2024 | 44.24% |
| Jun 30, 2024 | 75.45% |
| Mar 31, 2024 | -38.66% |
| Dec 31, 2023 | 27.11% |
| Sep 30, 2023 | 29.49% |
| Jun 30, 2023 | 64.97% |
| Mar 31, 2023 | 40.14% |
| Dec 31, 2022 | 39.90% |
| Sep 30, 2022 | 19.09% |
| Jun 30, 2022 | 37.27% |
| Mar 31, 2022 | 29.68% |
| Dec 31, 2021 | -42.35% |
| Sep 30, 2021 | -8.76% |
| Jun 30, 2021 | 45.08% |
| Mar 31, 2021 | 58.85% |